PDL1-t-haNK (ImmunityBio) Drug Due Diligence Report 2026

This PDL1-t-haNK (ImmunityBio) Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

149

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether PDL1-t-haNK (ImmunityBio) can convert its Natural Killer Cell Therapies profile and PDL1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	PDL1-t-haNK (ImmunityBio) (query alias: PDL1-t-haNK (ImmunityBio))
Modality / target	Natural Killer Cell Therapies; PDL1; PDL1 modulators
Highest global status	Phase 2
Originator	NantKwest, Inc.
Active developers	ImmunityBio, Inc.

The MCP disease footprint includes Glioblastoma Multiforme, Glioblastoma, IDH-Wildtype, Head and neck cancer metastatic. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06239220	Phase 2	Recruiting	25	Primary endpoint not disclosed in English source
NCT06061809	Phase 2	Active, not recruiting	34	Primary endpoint not disclosed in English source
NCT04927884	Phase 1/2	Terminated	3	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Response in first-in-human chemotherapy-free combination immunotherapy targeting lymphopenia in recurrent glioblastoma multiform (GBM): Nogapendekin alfa inbakicept (NAI) and PD-L1 t-haNK plus bevacizumab (BEV).

Phase 2; n=14; evaluation: Positive. Reported fields: ALC = ALC levels were measured through data cutoff (January 13, 2026).

Association of lymphopenia rescue and CA19-9 levels with overall survival following IL-15 superagonist N-803 and PD-L1 t-haNK chemo-immunotherapy for 3rdline or greater metastatic pancreatic cancer.

Phase 2; n=84; evaluation: Positive. Reported fields: Adverse Event: TEAEs = Grade 3 or higher TEAEs occurred in 95% of patients and were largely chemotherapy-associated ; Adverse Event: TEAEs = Grade 3 or higher TEAEs occurred in 95% of patients and were largely chemotherapy-associated

Open-Label Phase 1b/2 Study of Sacituzumab Govitecan-Hziy Plus Chemoimmunotherapy for the Treatment of Subjects With Advanced Triple-Negative Breast Cancer After Prior Therapy

Phase 1/2; n=3; evaluation: Not stated in English source. Reported fields: Number of Participants With Treatment Emergent Adverse Events = 3 Pts

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

PDL1-t-haNK (ImmunityBio) addresses Glioblastoma Multiforme, Glioblastoma, IDH-Wildtype, Head and neck cancer metastatic. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Natural Killer Cell Therapies—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 149 matched transaction record(s) under the scope “target-level comparable: PDL1.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: PDL1 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-08-21	Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets	Discovery	US$150.0M stated total
2026-06-26	CStone Pharma joins hands with Arrotex to commercialise Sugemalimab across Australia and New Zealand	Approved	Financial terms not disclosed
2026-02-18	BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License	Not disclosed	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO